Business
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities I
About this update from Okyo Pharma Limited
[{"type":"image","alt":"OKYO Pharma LTD","displaySize":"","headline":null,"caption":"OKYO Pharma LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5rBQz17s3GxW5mY3tWfBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f","width":300,"height":113}},"lazy":false},{"type":"text","content":"LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities Inc. This strategic move allows OKYO Pharma to continue accessing the capital markets efficiently through an ATM program, enabling the sale of common shares directly into the market from time to time, at prevailing market prices, subject to market conditions and the Company's discretion.","length":796,"tagName":"p"},{"type":"text","content":""We are excited to partner with Leerink Partners to establish this new ATM facility," said Keeren Shah, Chief Financial Officer of OKYO Pharma. "Leerink's deep expertise in the biotech sector, proven track record in executing ATM programs, and strong relationships in the investor community make them an ideal partner as we advance our pipeline, including our lead candidate urcosimod for neuropathic corneal pain. This transition enhances our financial flexibility to support ongoing clinical development and corporate objectives without committing to a fixed equity raise."","length":599,"tagName":"p"},{"type":"text","content":"The ATM facility provides OKYO Pharma the ability to raise capital opportunistically while minimizing market disruption. Sales under the program, if any, will be made pursuant to a prospectus supplement and accompanying base prospectus filed with the U.S. Securities and Exchange Commission (SEC). Leerink Partners will act as the exclusive ...